ARCT היקף נכסי החברה Arcturus Pharma

Arcturus Therapeutics (ARCT) is a leading developer of mRNA therapeutics advancing its unique LUNAR delivery system. This price chart reflects total assets at 266.82. Revenue growth is driven by the global launch of self-amplifying vaccines via partnership royalties. The business's success relies on a team of top scientists, whom the company attracts through lucrative options and large-scale research investments.

Arcturus Therapeutics (ARCT) maintains resilience against macroeconomic downturns due to the specific nature of mRNA development, where growth rates depend on medical cycles rather than GDP. This valuation of the company's financial assets reflects the total volume of controlled resources calculated inversely via ROA, allowing investors to track the scale of the business while accounting for capital freeze risks in the absence of clinical phase approvals.